Celldex Therapeutics Inc is a pioneering biopharmaceutical firm focused on crafting innovative antibody-based treatments for inflammatory, allergic, autoimmune, and other severe diseases. With a notable drug candidate, CDX-0159, currently in Phase II trials targeting the KIT receptor tyrosine kinase, Celldex is at the forefront of addressing unmet medical needs. Founded in 1983 and based in Hampton, New Jersey, the company also benefits from strategic research partnerships, including one with Yale University, to advance its mission of developing life-changing therapeutics.